The Gut Microbiome and Immunotherapy.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 443
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2021 AND VI 35 AND IP 7
Results: 29
1
2
Platinum-Agnostic Recurrent Ovarian Cancer May Benefit From Mirvetuximab Soravtansine Plus Bevacizumab.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 437
- Publication type:
- Article
3
No Survival Difference Is Noted With Longer Bevacizumab Duration in Ovarian Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 437
- Publication type:
- Article
4
Multitrial Analysis Indicates Niraparib Benefit for BRCA+ Ovarian Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 437
- Publication type:
- Article
5
Long-Term Survival Benefit Is Reported for Pembrolizumab/Axitinib in RCC.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 436
- Publication type:
- Article
6
HRQOL Analysis From CLEAR Further Supports Pembrolizumab/Lenvatinib for Frontline RCC.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 436
- Publication type:
- Article
7
Abiraterone/ADT and Docetaxel in de novo mCSPC Improves rPFS.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 435
- Publication type:
- Article
8
TURBT With Nivolumab/Chemo as Bladder-Sparing Strategy in MIBC.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 435
- Publication type:
- Article
9
OS by Patient Subgroups Support Frontline Avelumab Maintenance in Advanced Urothelial Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 435
- Publication type:
- Article
10
EGFR ex 20+ NSCLC After Platinum Chemotherapy Responds to Mobocertinib Monotherapy.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 434
- Publication type:
- Article
11
ARROW Trial Continues to Support Pralsetinib in RET Fusion+ NSCLC.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 434
- Publication type:
- Article
12
Adding Nivolumab to Chemo Improves Outcomes in Resectable NSCLC.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 434
- Publication type:
- Article
13
Compared With ASCT, KCd Consolidation Was Noninferior for Newly Diagnosed, Transplant- Eligible MM.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 433
- Publication type:
- Article
14
CARTITUDE-2 Reports Strong Efficacy Data for Cilta-Cel in Multiple Myeloma.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 433
- Publication type:
- Article
15
Philippe Moreau, MD, on Daratumumab Maintenance for Newly Diagnosed Myeloma.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 432
- Publication type:
- Article
16
Acalabrutinib Is Noninferior, Better Tolerated Than Ibrutinib in Previously Treated CLL.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 432
- Publication type:
- Article
17
Long-Term Clinical Benefit Is Observed With KTE-X19 for Treatment of Relapsed/Refractory B-ALL.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 432
- Publication type:
- Article
18
High Rate of Response Is Noted in MCL and CLL With Cirmtuzumab Plus Ibrutinib.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 431
- Publication type:
- Article
19
Patients With CLL and Other B-Cell Malignancies Benefit from TG-1701.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 431
- Publication type:
- Article
20
Responses to Tafasitamab/Lenalidomide in DLBCL Are Sustained at 3 Years.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 431
- Publication type:
- Article
21
Advanced Penile Cancer Presenting With Renal Failure.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 425, doi. 10.46883/onc.2021.3507.0425
- By:
- Publication type:
- Article
22
Median Lobe Urethral Embolus After Focal Ablation of Gleason 7 Prostate Cancer.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 422, doi. 10.46883/onc.2021.3507.0422
- By:
- Publication type:
- Article
23
Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 410, doi. 10.46883/onc.2021.3507.0410
- By:
- Publication type:
- Article
24
Profilin 1 Protein and Its Implications for Cancers.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 402, doi. 10.46883/onc.2021.3507.0402
- By:
- Publication type:
- Article
25
Level of Scientific Evidence Underlying the National Comprehensive Cancer Network Clinical Practice Guidelines for Hematologic Malignancies: Are We Moving Forward?
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 390, doi. 10.46883/onc.2021.3507.390
- By:
- Publication type:
- Article
26
Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining Genetic Testing in Gastrointestinal Malignancies.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 382, doi. 10.46883/onc.2021.3507.0382
- By:
- Publication type:
- Article
27
Insights From the ONCOLOGY® Tumor Chairs on the 2021 ASCO Annual Meeting.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 380
- Publication type:
- Article
28
The Future of Telehealth for Hematology/Oncology Care.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 379
- By:
- Publication type:
- Article
29
Questions Linger Around COVID-19's Origin.
- Published in:
- Oncology (08909091), 2021, v. 35, n. 7, p. 378
- By:
- Publication type:
- Article